1. Renal toxicity of targeted therapies for renal cell carcinoma in patients with normal and impaired kidney function

   • Łukasz Mielczarek
   • Anna Brodziak
   • Anna M. Czarnecka

   Review Article Open access 25 March 2021 Pages: 723 - 742

2. Clinical pharmacology strategies in supporting drug development and approval of antibody–drug conjugates in oncology

   • Stephanie N. Liu
   • Chunze Li

   Review Article Open access 01 April 2021 Pages: 743 - 765

   

3. Associations among plasma concentrations of regorafenib and its metabolites, adverse events, and ABCG2 polymorphisms in patients with metastatic colorectal cancers

   • Kazuo Kobayashi
   • Erika Sugiyama
   • Kensei Yamaguchi

   Original Article 26 February 2021 Pages: 767 - 777

   

4. A phase I pharmacokinetic and safety study of Paclitaxel Injection Concentrate for Nano-dispersion (PICN) alone and in combination with carboplatin in patients with advanced solid malignancies and biliary tract cancers

   • Wen Wee Ma
   • Mojun Zhu
   • Antonio Jimeno

   Original Article 26 February 2021 Pages: 779 - 788

   

5. Clinical significance of circulating tumor cells in the response to trastuzumab for HER2-negative metastatic gastric cancer

   • Daisuke Matsushita
   • Yoshikazu Uenosono
   • Shoji Natsugoe

   Original Article 28 February 2021 Pages: 789 - 797

   

6. Pharmacokinetics of UGN-101, a mitomycin-containing reverse thermal gel instilled via retrograde catheter for the treatment of low-grade upper tract urothelial carcinoma

   • Ahmad Shabsigh
   • Nir Kleinmann
   • Seth P. Lerner

   Original Article Open access 07 March 2021 Pages: 799 - 805

   

7. A pharmacologically-based approach to high dose methotrexate administration to investigate nephrotoxicity and acute kidney injury biomarkers in children and adolescents with newly diagnosed osteosarcoma

   • Elizabeth Fox
   • Christine Busch
   • Frank Balis

   Original Article 07 March 2021 Pages: 807 - 815

   

8. Venous thromboembolism incidence and risk factors in adults with acute lymphoblastic leukemia treated with and without pegylated E. coli asparaginase-containing regimens

   • Sarah M. Kashanian
   • Noa G. Holtzman
   • Ashkan Emadi

   Original Article 07 March 2021 Pages: 817 - 826

9. Foretinib induces G2/M cell cycle arrest, apoptosis, and invasion in human glioblastoma cells through c-MET inhibition

   • Narges K. Gortany
   • Ghodratollah Panahi
   • Mahmoud Ghazi-Khansari

   Original Article 10 March 2021 Pages: 827 - 842

   

10. Clinical utility of ABCB1 and ABCG2 genotyping for assessing the clinical and pathological response to FAC therapy in Mexican breast cancer patients

    • Eneida Turiján-Espinoza
    • Víctor Manuel Ruíz-Rodríguez
    • Diana Patricia Portales-Pérez

    Original Article 19 March 2021 Pages: 843 - 853

    

11. Pharmacokinetics of docetaxel and ritonavir after oral administration of ModraDoc006/r in patients with prostate cancer versus patients with other advanced solid tumours

    • Marit A. C. Vermunt
    • Lisa T. van der Heijden
    • Jos H. Beijnen

    Original Article 20 March 2021 Pages: 855 - 869

    

12. Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases

    • Hiroaki Ikesue
    • Kohei Doi
    • Tohru Hashida

    Short Communication Open access 31 March 2021 Pages: 871 - 877

    

13. Correction to: Cyclooxygenase activity mediates colorectal cancer cell resistance to the omega‑3 polyunsaturated fatty acid eicosapentaenoic acid

    • Milene Volpato
    • Nicola Ingram
    • Mark A Hull

    Correction 17 November 2020 Pages: 879 - 880